The safety of ramucirumab without H1-antihistamines as a premedication in patients with solid cancers: A retrospective study
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz434.031
Abstract: Abstract Background Ramucirumab is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. To reduce the risk of an infusion-related reaction (IRR) with ramucirumab, H1-antihistamines are recommended as premedication. However, IRR… read more here.
Keywords: without antihistamines; ramucirumab; ramucirumab without; cancer ... See more keywords